Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develo…
18 employees medicenna.com
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-05-28 Financing
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
News release - English.pdf
Transactions 2026-05-22 Financing
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
News release - English.pdf
Transactions 2026-05-22 Financing
Underwriting or agency agreements (or amendment thereto).pdf
Transactions 2026-05-22 Financing
Prospectus (non pricing) supplement (other than ATM) – English.pdf
Transactions 2026-05-19 Financing
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
News release - English.pdf
Transactions 2026-05-13 Financing
Medicenna Announces the Launch of a Marketed Public Offering of Securities
News release - English.pdf
News 2026-05-12
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
News release - English.pdf
News 2026-04-30
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
News release - English.pdf
Results 2026-04-21
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
News release - English.pdf
News 2026-04-14
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
News release - English.pdf
News 2026-03-18
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
News release - English.pdf
Results 2026-02-13 Financials
Interim MD&A - English.pdf
Results 2026-02-13 Financials
Interim financial statements/report – English.pdf
Results 2026-01-15
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
News release - English.pdf
News 2025-12-16
Early warning report.pdf
Ownership 2025-12-16
Dr. Fahar Merchant acquires shares of Medicenna
Press release - English.pdf
Results 2025-12-10
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
News release - English.pdf
News 2025-12-09
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
News release - English.pdf
News 2025-11-13
News release - English.pdf
Results 2025-11-13 Financials
Interim MD&A - English.pdf
Results 2025-11-13 Financials
Interim financial statements/report – English.pdf
News 2025-11-06
News release - English.pdf
News 2025-10-23
News release - English.pdf
News 2025-10-20
News release - English.pdf
News 2025-10-01
News release - English.pdf
News 2025-09-25
News release - English.pdf
News 2025-09-05
News release - English.pdf
News 2025-08-26
Other.pdf
News 2025-08-26
Other.pdf
News 2025-08-26
Other.pdf
News 2025-08-01
News release - English.pdf
Results 2025-07-31 Financials
Interim MD&A - English.pdf
Results 2025-07-31 Financials
Interim financial statements/report – English.pdf
News 2025-07-31
News release - English.pdf
News 2025-06-26
News release - English.pdf
Results 2025-06-26 Financials
Annual information form - English.pdf
Results 2025-06-26 Financials
Annual MD&A - English.pdf
Results 2025-06-26 Financials
Audited annual financial statements – English.pdf
News 2025-06-05
Decision Document (Final).pdf
Transactions 2025-06-04 Financing
Final short form prospectus – English.pdf
Transactions 2025-06-04 Financing
Undertaking to file documents and material contracts.pdf